Successful treatment with three-weekly paclitaxel of an anthracycline-refractory classical Kaposi's sarcoma

Paclitaxel has been approved as second-line therapy after anthracyclines in AIDS-Kaposi's sarcoma (KS) patients. To date, only one patient with classical KS and treated with standard dose (175 mg/m2) 3-weekly paclitaxel as first line therapy has been reported in the literature. Herein, the first case is presented of a patient with anthracycline-refractory classical KS who was treated with standard dose 3-weekly and paclitaxel after five cycles of therapy achieved a partial response according to the AIDS Clinical Trials Group criteria.